<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author>Afolabi, A.</author>
     <author>Mustafina, I.</author>
     <author>Zhao, L.</author>
     <author>Li, L.</author>
     <author>Sun, R.</author>
     <author>Hu, S.</author>
     <author>Zhang, S.</author>
     <author>Jia, H.</author>
     <author>Guilio, G.</author>
     <author>Yu, B.</author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2018</year>
    <pub-dates>
     <date>2018-07-11</date>
    </pub-dates>
   </dates>
   <doi>10.1002/ccd.27496</doi>
   <abstract>Objectives: The aim of this study was to determine if spotty calcification decreases the response of plaque progression to statin therapy. Background: Previous studies showed that the presence of spotty calcification is a marker of vulnerable plaque. However, the relationship between spotty calcification and plaque progression is not clear. Methods: Ninety-six nonculprit lipid-rich plaques in 69 patients who received serial optical coherence tomography (OCT) imaging were included. Plaques were divided into three groups: spotty calcification (n = 38), calcified (n = 12) and noncalcified (n = 46) plaques. Spotty calcification was identified by the presence of a lesion </abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/1162</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/1325</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
